Audited Financial Results for the Financial Year ended 31st March 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.8 pts less than Nifty Microcap 250 and 3.3 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Shanmuga Hospital reported FY25 revenue of ₹4,785.33 lakhs, up about 11% from ₹4,303.74 lakhs in FY24. However, profit after tax declined nearly 20% to ₹420.67 lakhs from ₹524.85 lakhs, as expenses grew faster than revenue. EPS fell to ₹4.03 from ₹5.36. The company recently listed on BSE SME platform on 21 February 2025, raising ₹2,061.72 lakhs via IPO, of which ₹1,115.50 lakhs remains unutilized (parked in fixed deposits). Cash and bank balances rose sharply to ₹1,258.93 lakhs. The board approved opening a new Nephro Care Unit and closing the Shanmuga Pharmacy & Diagnostics outlet in Salem from 31 May 2025. Statutory auditor M/s PPN and Company issued an unmodified audit opinion.
Mixed picture for shareholders: top-line growth is healthy but bottom-line is under pressure, and operating cash flow turned sharply negative despite strong cash on the books from the recent IPO. The new Nephro Care unit signals expansion focus, while the pharmacy closure indicates portfolio rationalisation.